Even though therapies directed to molecules found to be overexpressed turned out to be successful, such as anti-TNF and Janus kinase inhibitors, both in RA and PsA, data from failed clinical trials have taught us that targeting (apparent) key pathways may not always result in obvious clinical benefit (72, 73). Here, TNF is linked to rheumatoid arthritis.